Some exciting news for Neuland Labs this week: we’ve just entered into a manufacturing collaboration with Tokyo-based API Corporation (APIC) – a healthcare unit of Mitsubishi Chemical Holdings Group.
As a company, Neuland has been focusing on developing its business in Japan and the U.S. At the same time, APIC was seeking out a partner in India to serve its own customers in a more cost-effective manner. This win-win agreement with APIC allows Neuland to work with a high-profile company by giving them dedicated manufacturing capacity while at the same time expanding our own API and intermediaries contract manufacturing business in Japan and around the globe.
It came down to Neuland’s long history of quality production and regulatory excellence stretching back more than 25 years. We’ve been inspected by the US FDA and other leading regulatory agencies, we hold cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001. Across all those years, however, we’ve never seen a warning letter. Not once. We’re proud of that record.
For me, our manufacturing collaboration with APIC is exciting because it brings together two companies that share that commitment to providing quality and excellence to customers. It also validates the importance we’ve always placed on quality, and it confirms the magnitude of our exemplary regulatory history.
About the Author
Saharsh Davuluri is the President of Contract Manufacturing at Neuland Laboratories, Ltd., an API and Contract Research & Manufacturing provider based in Hyderabad, India. Neuland provides products and services to life sciences companies worldwide. With 45 U.S. DMFs, 15 Canadian DMFs, 9 DMFs in Australia, 363 DMFs in various European and other regulatory markets and 14 CEPs, Neuland has an unrelenting commitment to quality. The Company has never received a warning letter from any of the regulatory agencies who have routinely inspected Neuland’s facilities since operations began nearly 30 years ago.